articl
review
histor
develop
thalidomid
immunosuppress
agent
current
state
knowledg
thalidomid
antigraftversushost
diseas
gvhd
agent
evid
suggest
metabolit
thalidomid
act
earli
stage
antigen
recognitionactiv
pathway
graft
lymphocyt
regul
normal
lymphocyt
respons
effect
seem
benefici
effect
acut
chronic
gvhd
optim
mode
use
clinic
set
remain
determin
prevent
treatment
graft
versu
host
diseas
gvhd
remain
problem
signific
present
basi
prophylaxi
therapi
attempt
control
immun
statu
graft
prevent
acut
gvhd
involv
use
three
method
methotrex
cyclosporin
immunosuppress
agent
use
extens
gvhd
prophylaxi
third
method
use
cell
deplet
graft
prove
caus
problem
methotrex
first
studi
prophylact
agent
gvhd
murin
canin
model
prove
success
becam
avail
clinic
use
random
trial
compar
methotrex
versu
posttranspl
abbrevi
gvhd
graftversu
host
diseas
interleukin
mab
monoelon
antibodi
mhc
major
histocompat
complex
mlc
mix
lymphocyt
cultur
pha
phytohaemagglutinin
con
concanavalin
correspond
dr
j
proctor
univers
depart
haematolog
royal
victoria
infirmari
queen
victoria
road
newcastleupontyn
uk
immunosuppress
carri
howev
nonrandom
studi
shown
methotrex
reduc
incid
acut
gvhd
though
elimin
use
cyclosporin
immunosuppress
work
inhibit
product
receptor
express
review
cyclosporin
see
shevach
improv
prophylaxi
gvhd
cyclosporin
methotrex
appear
compar
use
prophylaxi
howev
combin
two
result
reduc
incid
gvhd
compar
either
use
alon
whilst
result
encourag
hopedfor
elimin
acut
gvhd
occur
confirm
cell
respons
onset
gvhd
led
use
cell
deplet
marrow
transplant
number
studi
use
deplet
varieti
method
includ
lectin
agglutin
use
mab
complement
toxinlink
mab
rat
igm
mab
use
combin
complement
remov
cell
marrow
significantli
reduc
incid
gvhd
consecut
transplant
patient
leukaemia
nonhodgkin
lymphoma
howev
use
tdeplet
marrow
given
rise
anoth
problem
studi
heit
et
al
use
result
increas
graft
reject
studi
shown
increas
leukaem
relaps
follow
cell
deplet
treatment
gvhd
involv
balanc
give
suffici
immunosuppress
control
graft
activ
without
give
excess
immunosuppress
would
increas
alreadi
high
risk
develop
infect
corticosteroid
cyclosporin
main
treatment
use
methyl
prednisolon
prove
effect
use
combin
methotrex
cyclosporin
prove
benefit
prevent
chronic
gvhd
prevent
chronic
gvhd
must
lie
prior
prevent
acut
gvhd
establish
chronic
gvhd
howev
respond
low
dose
prednisolon
combin
azathioprin
combin
prevent
progress
chronic
gvhd
significantli
reduc
mortal
condit
howev
acut
gvhd
treatment
prove
satisfactori
two
major
problem
exist
therapi
view
lack
specif
therefor
immunosuppress
action
potenti
danger
compromis
patient
sinc
increas
risk
superven
infect
drug
use
prevent
treatment
potenti
toxic
therefor
possibl
lifethreaten
patient
research
thu
direct
drug
immunosuppress
action
may
benefit
therapi
gvhd
regard
drug
thalidomid
studi
anim
model
clinic
set
thalidomid
thalidomid
nphthalidoglutarimid
first
synthes
research
chemi
grunenth
west
germani
market
follow
distribut
countri
includ
uk
sedativehypnot
drug
brand
name
distav
uk
thalidomid
wide
prescrib
seem
ideal
drug
show
good
activ
combin
absenc
acut
toxic
side
effect
upon
longterm
use
howev
sideeffect
becam
evid
report
peripher
neuropathi
appear
literatur
howev
confirm
teratogen
action
thalidomid
first
report
lenz
knapp
led
withdraw
thalidomid
market
thalidomid
unavail
mainstream
drug
sinc
time
avail
defin
research
purpos
initi
shock
teratogen
thalidomid
investig
use
thalidomid
therapi
mani
diseas
first
report
patient
reaction
lepromat
leprosi
receiv
thalidomid
sed
experienc
spectacular
relief
symptom
trial
confirm
result
sinc
time
thalidomid
shown
effect
varieti
diseas
includ
chronic
discoid
lupu
erythematosu
bechet
syndrom
prurigo
nodulari
ulcer
coliti
review
barnhil
mcdougal
common
factor
thought
link
disord
mention
purport
immunolog
mediat
result
interpret
suggest
thalidomid
may
immunosuppress
properti
tragedi
thalidomid
teratogen
observ
drug
releas
onto
market
serious
inhibit
research
drug
mechan
action
possibl
thalidomid
may
immunosuppress
action
led
interest
drug
possibl
therapeut
agent
gvhd
one
earli
report
suggest
thalidomid
could
least
partial
arrest
gvhd
mous
model
though
assess
gvhd
spleen
weight
particularli
sensit
report
phenomenon
remain
uninvestig
vogelsang
et
al
began
studi
thalidomid
gvhd
rat
model
lewi
aci
rtia
rat
major
mismatch
model
mhc
rat
term
complex
establish
model
use
studi
cyclosporin
lewi
rat
totalbodi
irradi
given
rtlincompat
aci
marrow
within
two
week
transplant
acut
gvhd
develop
assess
clinic
appear
erythema
skin
ear
footpad
patholog
grade
skin
biopsi
grade
ii
model
use
studi
potenti
thalidomid
prophylaxi
treatment
gvhd
vogelsang
et
al
report
thalidomid
given
gavag
mgkgday
day
clinic
histolog
onset
acut
gvhd
success
resolv
acut
gvhd
anim
addit
surpris
result
stop
thalidomid
therapi
reappear
gvhd
anim
remain
three
chronic
gvhd
develop
three
week
later
chimer
demonstr
accept
aci
skin
graft
day
posttranspl
thirdparti
graft
still
reject
howev
normal
lewi
rat
thalidomid
prolong
surviv
aci
skin
graft
studi
thalidomid
shown
benefit
prophylact
agent
gvhd
thalidomid
given
day
transplant
continu
day
rat
develop
gvhd
follow
transplant
eight
develop
clinic
infect
rat
corona
viru
caus
mild
gvhd
respond
thalidomid
therapi
rat
gvhd
occur
drug
stop
chimer
demonstr
final
toler
demonstr
failur
spleen
cell
chimer
anim
respond
recipi
donor
lymphocyt
recent
seri
experi
vogelsang
et
al
use
lower
dose
thalidomid
mgkg
dose
plu
cyclosporin
demonstr
superior
thalidomid
thalidomid
plu
cyclosporin
methotrex
azothiaprin
steroid
vogelsang
et
al
also
test
compound
structur
relat
thalidomid
studi
mechan
action
thalidomid
gvhd
phthalimid
structur
doubl
ring
half
thalidomid
molecul
rat
model
effect
prevent
gvhd
anim
treat
unabl
control
establish
gvhd
anim
aminoglutethamid
half
molecul
ineffect
prevent
therapi
anim
develop
gvhd
fluoresc
deriv
thalidomid
addit
success
control
gvhd
four
anim
capabl
inhibit
phytohaemagglutinin
pha
concanavalin
con
alloantigen
respons
lymphocyt
vitro
studi
suggest
activ
part
thalidomid
molecul
gvhd
phthalimid
ring
addit
invitro
result
suggest
inhibitori
action
lymphocyt
activ
signal
work
shown
addit
synergist
effect
thalidomid
cyclosporin
prophylaxi
gvhd
clinic
work
thalidomid
gvhd
infanc
anecdot
evid
began
appear
literatur
lim
et
al
report
control
establish
acut
gvhd
thalidomid
mg
increas
mg
per
day
combin
prednisolon
saurat
et
al
claim
success
treat
chronic
gvhd
mg
per
day
month
howev
time
drug
withdrawn
paraesthesia
develop
feet
report
sweden
show
patient
superven
infect
thalidomid
may
fail
halt
progress
gvhd
two
report
success
therapi
chronic
gvhd
children
also
appear
literatur
vogelsang
colleagu
report
commenc
clinic
trial
use
thalidomid
gvhd
studi
immunosuppress
action
thalidomid
extrem
contradictori
littl
recent
work
undertaken
hellmann
et
al
found
thalidomid
prolong
surviv
skin
homograft
transplant
across
mhc
barrier
mice
later
show
thalidomid
appear
decreas
number
immunoblast
local
lymph
node
skin
homograft
howev
worker
fail
find
effect
thalidomid
system
thalidomid
found
effect
type
iii
iv
hypersensit
reaction
coulson
et
al
show
thalidomid
deriv
could
inhibit
product
transform
cell
mlc
wherea
inhibit
respons
pha
may
impli
thalidomid
deriv
may
act
earli
antigenrecognit
pathway
howev
must
accept
experi
design
studi
immunosuppress
action
thalidomid
reach
firm
conclus
studi
direct
teratogen
thalidomid
may
provid
addit
inform
presenc
hepat
microsom
drugmetabol
system
thalidomid
metabolit
thalidomid
inhibit
attach
cell
con
acoat
plate
suggest
interfer
cellcel
interact
andor
cell
activ
use
system
thalidomid
metabolit
shown
directli
toxic
human
lymphocyt
though
thalidomid
ineffect
import
point
research
outlin
need
summar
consid
context
gvhd
invitro
work
suggest
thalidomid
may
activ
compound
may
requir
metabol
activ
deriv
probabl
liver
b
activ
compound
appear
act
earli
stage
recognitionactiv
pathway
lymphocyt
prevent
respons
antigen
mitogen
stimuli
c
action
probabl
surfac
receptor
lymphocyt
membran
suggest
rel
rapid
effect
compound
effect
cell
somehow
downregul
normal
respons
antigen
stimulu
effect
could
either
specif
interfer
particular
messeng
system
direct
toxic
effect
cell
evid
latter
mechan
invivo
data
indic
thalidomid
metabolit
prevent
cure
clinic
gvhd
acut
chronic
b
contrast
immunosuppress
thalidomid
appear
act
perman
way
gvhd
control
therapi
stop
taken
togeth
hypothesi
tent
made
activ
metabolit
thalidomid
produc
liver
act
graft
cell
via
surfac
receptor
produc
perman
nonrespons
state
situat
newli
transplant
recipi
downregul
prevent
occurr
progress
graftversushost
reaction
graftversushost
diseas
still
remain
major
complic
factor
allogen
bone
marrow
transplant
clear
great
deal
work
need
done
cellular
level
establish
exact
pathogen
mechan
occur
howev
thalidomid
appear
offer
promis
new
therapi
gvhd
research
must
done
studi
close
mechan
action
versatil
drug
control
clinic
trial
thalidomid
need
establish
efficaci
clinic
arena
